Molecular Diagnostics Market (Technology: PCR & Real-time PCR, Hybridization, Microarray, Transcription-mediated Amplification, Next Generation Sequencing, and Others; Application: Infectious Diseases [Virology and Bacteriology], Oncology, Blood Screening, Microbiology, Genetic Testing, and Women’s Health; and End-user: Hospitals, Diagnostics Laboratories, Blood Banks, Academics & Research, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2030
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Molecular Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. End-user Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Molecular Diagnostics Market Analysis and Forecast, 2017–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Future Market Outlook
5.2. Key Industry Events
5.3. Porter’s Five Force Analysis
5.4. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)
6. Global Molecular Diagnostics Market Analysis and Forecast, by End-user
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by End-user, 2017–2030
6.3.1. PCR & Real-time PCR
6.3.2. Hybridization
6.3.3. Microarray
6.3.4. Transcription-mediated Amplification
6.3.5. Next-Generation Sequencing
6.3.6. Others
6.4. Market Attractiveness Analysis, by End-user
7. Global Molecular Diagnostics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2030
7.3.1. Infectious Diseases
7.3.1.1. Virology
7.3.1.2. Bacteriology
7.3.2. Oncology
7.3.3. Blood Screening
7.3.4. Microbiology
7.3.5. Genetic Testing
7.3.6. Women’s Health
7.4. Market Attractiveness Analysis, by Application
8. Global Molecular Diagnostics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2030
8.3.1. Hospitals
8.3.2. Diagnostics Laboratories
8.3.3. Blood Banks
8.3.4. Academics & Research
8.3.5. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Molecular Diagnostics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Molecular Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by End-user, 2017–2030
10.2.1. PCR & Real-time PCR
10.2.2. Hybridization
10.2.3. Microarray
10.2.4. Transcription-mediated Amplification
10.2.5. Next-Generation Sequencing
10.2.6. Others
10.3. Market Value Forecast, by Application, 2017–2030
10.3.1. Infectious Diseases
10.3.1.1. Virology
10.3.1.2. Bacteriology
10.3.2. Oncology
10.3.3. Blood Screening
10.3.4. Microbiology
10.3.5. Genetic Testing
10.3.6. Women’s Health
10.4. Market Value Forecast, by End-user, 2017–2030
10.4.1. Hospitals
10.4.2. Diagnostics Laboratories
10.4.3. Blood Banks
10.4.4. Academics & Research
10.4.5. Others
10.5. Market Value Forecast, by Country, 2017–2030
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By End-user
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Molecular Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by End-user, 2017–2030
11.2.1. PCR & Real-time PCR
11.2.2. Hybridization
11.2.3. Microarray
11.2.4. Transcription-mediated Amplification
11.2.5. Next-Generation Sequencing
11.2.6. Others
11.3. Market Value Forecast, by Application, 2017–2030
11.3.1. Infectious Diseases
11.3.1.1. Virology
11.3.1.2. Bacteriology
11.3.2. Oncology
11.3.3. Blood Screening
11.3.4. Microbiology
11.3.5. Genetic Testing
11.3.6. Women’s Health
11.4. Market Value Forecast, by End-user, 2017–2030
11.4.1. Hospitals
11.4.2. Diagnostics Laboratories
11.4.3. Blood Banks
11.4.4. Academics & Research
11.4.5. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2030
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By End-user
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Molecular Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by End-user, 2017–2030
12.2.1. PCR & Real-time PCR
12.2.2. Hybridization
12.2.3. Microarray
12.2.4. Transcription-mediated Amplification
12.2.5. Next-Generation Sequencing
12.2.6. Others
12.3. Market Value Forecast, by Application, 2017–2030
12.3.1. Infectious Diseases
12.3.1.1. Virology
12.3.1.2. Bacteriology
12.3.2. Oncology
12.3.3. Blood Screening
12.3.4. Microbiology
12.3.5. Genetic Testing
12.3.6. Women’s Health
12.4. Market Value Forecast, by End-user, 2017–2030
12.4.1. Hospitals
12.4.2. Diagnostics Laboratories
12.4.3. Blood Banks
12.4.4. Academics & Research
12.4.5. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2030
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By End-user
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Molecular Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by End-user, 2017–2030
13.2.1. PCR & Real-time PCR
13.2.2. Hybridization
13.2.3. Microarray
13.2.4. Transcription-mediated Amplification
13.2.5. Next-Generation Sequencing
13.2.6. Others
13.3. Market Value Forecast, by Application, 2017–2030
13.3.1. Infectious Diseases
13.3.1.1. Virology
13.3.1.2. Bacteriology
13.3.2. Oncology
13.3.3. Blood Screening
13.3.4. Microbiology
13.3.5. Genetic Testing
13.3.6. Women’s Health
13.4. Market Value Forecast, by End-user, 2017–2030
13.4.1. Hospitals
13.4.2. Diagnostics Laboratories
13.4.3. Blood Banks
13.4.4. Academics & Research
13.4.5. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2030
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By End-user
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Molecular Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by End-user, 2017–2030
14.2.1. PCR & Real-time PCR
14.2.2. Hybridization
14.2.3. Microarray
14.2.4. Transcription-mediated Amplification
14.2.5. Next-Generation Sequencing
14.2.6. Others
14.3. Market Value Forecast, by Application, 2017–2030
14.3.1. Infectious Diseases
14.3.1.1. Virology
14.3.1.2. Bacteriology
14.3.2. Oncology
14.3.3. Blood Screening
14.3.4. Microbiology
14.3.5. Genetic Testing
14.3.6. Women’s Health
14.4. Market Value Forecast, by End-user, 2017–2030
14.4.1. Hospitals
14.4.2. Diagnostics Laboratories
14.4.3. Blood Banks
14.4.4. Academics & Research
14.4.5. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2030
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By End-user
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2020
15.3. Company Profiles
15.3.1. Abbott Laboratories
15.3.1.1. Company Overview
15.3.1.2. Business Overview
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Becton, Dickinson and Company
15.3.2.1. Company Overview
15.3.2.2. Business Overview
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Bio-Rad Laboratories, Inc.
15.3.3.1. Company Overview
15.3.3.2. Business Overview
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. BioMérieux SA
15.3.4.1. Company Overview
15.3.4.2. Business Overview
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Danaher Corporation
15.3.5.1. Company Overview
15.3.5.2. Business Overview
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. F. Hoffmann-La Roche Ltd.
15.3.6.1. Company Overview
15.3.6.2. Business Overview
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. QIAGEN N.V.
15.3.7.1. Company Overview
15.3.7.2. Business Overview
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Siemens AG
15.3.8.1. Company Overview
15.3.8.2. Business Overview
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Thermo Fisher Scientific Inc.
15.3.9.1. Company Overview
15.3.9.2. Business Overview
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview